The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Dipeptidyl-Peptidase Activity of Meprin β Links N-truncation of Aβ with Glutaminyl Cyclase-Catalyzed pGlu-Aβ Formation
Abstract
The formation of amyloid-β (Aβ) peptides is causally involved in the development of Alzheimer’s disease (AD). A significant proportion of deposited Aβ is N-terminally truncated and modified at the N-terminus by a pGlu-residue (pGlu-Aβ). These forms show enhanced neurotoxicity compared to full-length Aβ. Although the truncation may occur by aminopeptidases after formation of Aβ, recently discovered processing pathways of amyloid-β protein precursor (AβPP) by proteases such as meprin β may also be involved. Here, we assessed a role of meprin β in forming Aβ 3 -40/42 , which is the precursor of pGlu-Aβ 3 -40/42 generated by glutaminyl cyclase (QC). Similar to QC, meprin β mRNA is significantly upregulated in postmortem brain from AD patients. A histochemical analysis supports the presence of meprin β in neurons and astrocytes in the vicinity of pGlu-Aβ containing deposits. Cleavage of AβPP-derived peptides by meprin β in vitro results in peptides Aβ 1 -x , Aβ 2 -x , and Aβ 3 -x . The formation of N-truncated Aβ by meprin β was also corroborated in cell culture. A subset of the generated peptides was converted into pGlu-Aβ 3 -40 by an addition of glutaminyl cyclase, supporting the preceding formation of Aβ 3 -40 . Further analysis of the meprin β cleavage revealed a yet unknown dipeptidyl-peptidase–like activity specific for the N-terminus of Aβ 1 -x . Thus, our data suggest that meprin β contributes to the formation of N-truncated Aβ by endopeptidase and exopeptidase activity to generate the substrate for QC-catalyzed pGlu-Aβ formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Meprin-β mRNA and protein levels are increased in AD patients compared to age-matched healthy individuals.
“several studies have reported increased mRNA and protein levels of meprin-β in AD patients compared to age-matched healthy individuals (Bien et al., 2012; Schlenzig et al., 2018).”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Schlenzig et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain
Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T., & Kawashima, S. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12970-0 · Cited by 270
Thal, D. R., Schultz, C., Dehghani, F., Yamaguchi, H., Braak, H., & Braak, E. (2000) · Acta Neuropathologica · doi:10.1007/s004010000242 · Cited by 136
Flagged first, then by citations
Research works printed but not linked: 42
- 10.1074/jbc.M501694200 · DOI
- 10.1159/000369465 · DOI
- 10.1016/j.neuroscience.2006.08.027 · DOI
- 10.1021/bi800250p · DOI
- 10.1111/j.1471-4159.2012.07707.x · DOI
- 10.1046/j.1471-4159.2002.01107.x · DOI
- 10.1016/j.biocel.2010.08.015 · DOI
- 10.1074/jbc.M115.655183 · DOI
- 10.1523/JNEUROSCI.1794-11.2011 · DOI · Paper page
- 10.1074/jbc.M111.308601 · DOI
- 10.1038/nature11060 · DOI · Paper page
- 10.1016/j.biocel.2016.08.037 · DOI
- 10.1016/j.neurobiolaging.2015.08.021 · DOI
- 10.1186/s13024-016-0115-2 · DOI
- 10.1111/j.1471-4159.2008.05471.x · DOI
- 10.1038/nm.1872 · DOI · Paper page
- 10.1111/j.1471-4159.2009.05950.x · DOI
- SchechterI, ZivE (2011) CathepsinsS, B and L with aminopeptidases display ß-secretase activity associated with the pathogenesis of Alzheimer’s disease. Biol Chem 555, 555–569.
- 10.1074/jbc.M112.395608 · DOI · Paper page
- 10.1515/BC.2008.124 · DOI
- 10.1042/bj3110299 · DOI
- 10.1002/1531-8249(200003)47:3<399::AID-ANA22>3.0.CO;2-5 · DOI
- 10.1186/s13024-016-0084-5 · DOI · Paper page
- 10.3389/fnmol.2016.00159 · DOI
- 10.1074/mcp.M111.009233 · DOI
- 10.1007/s10561-008-9067-2 · DOI
- MirraSS, HeymanA, McKeelD, SumiSM, CrainBJ, BrownleeLM, VogelFS, HughesJP, van BelleG, BergL (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41, 479–486.
- National Institute on Aging (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18, S1–S2.
- 10.1096/fj.01-0995fje · DOI
- 10.1016/0896-6273(95)90301-1 · DOI · Paper page
- 10.1016/S0197-4580(98)00033-5 · DOI
- 10.3233/JAD-131535 · DOI
- 10.1093/brain/awt362 · DOI
- 10.1007/s00401-014-1296-9 · DOI
- 10.1021/bi900818a · DOI · Paper page
- 10.1186/1471-2202-14-108 · DOI
- 10.1016/j.bbapap.2006.08.003 · DOI
- 10.1021/bi015800g · DOI · Paper page
- 10.1007/s00401-011-0806-2 · DOI
- 10.1042/bj20021398 · DOI
- 10.1046/j.1432-1327.1999.00268.x · DOI
- 10.1016/S0197-4580(02)00018-0 · DOI
Cited by
Sorted by citations
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
Metadata
- Authors
- Schlenzig, D., Cynis, H., Hartlage-Rübsamen, M., Zeitschel, U., Menge, K., Fothe, A., Ramsbeck, D., Spahn, C., Wermann, M., Roßner, S., Buchholz, M., Schilling, S., & Demuth, H.-U.
- Affiliations
- Department of Molecular Drug Design and Target Validation Fraunhofer Institute for Cell Therapy and Immunology, Halle (Saale), Germany
- Paul Flechsig Institute for Brain Research, Leipzig, Germany
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-09-29
- Volume
- 66
- Issue
- 1
- Pages
- 359-375
- ISSN
- 1387-2877
- 1875-8908
- Cited by
- 27
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review